Jump to

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

To the Editor:

FitzGerald’s commentary1 and its comment, “…there are so many problems with the interpretation of PRECISION [Prospective Evaluation of Celcoxib Integrated Safety versus Ibuprofen or Naproxen] that it fails to inform clinical practice” is, in my opinion, unsupported by the evidence and speaks more to a question of personal bias than to an unbiased evaluation of PRECISION.2

According to FitzGerald, after PRECISION, “… we are no closer to being able to advise the millions of patients with chronic arthritic pain regarding relative efficacy and safety of the treatments available to them.”1 This is a serious charge as it implies a massive waste of financial resources and patients’ contributions. His denigration of the trial would seem to confine the 1261 physicians involved (site PIs and committee and …